I arrived at my Parkinson’s Caregivers Support Group a little late. Getting out of the house with Gerry, my husband, had taken a bit longer than our new normal. And, of course, when I tried to hurry so that I could be on time, it took even longer.
Blog Introduction Text
Welcome to the National Parkinson Foundation's blog, where you can keep up-to-date on the latest research, read about what's hot in the Parkinson's community, learn caregiving tips and more.
In January 2012 we reported on the possibility of a blood test for Parkinson’s disease detection. Four years have now passed, and this week a different group from La Trobe University led by Paul Fisher say they have developed and potentially effective blood test for Parkinson’s disease detection. In this month’s What’s Hot in PD? Column, we will update our previous article and comment on this new observation.
April 29, 2016 – Today, the FDA approved Nuplazid (pimavanserin) as the first drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis, which affects up to 40% of people with Parkinson’s.
Every year, NPF hosts the Centers of Excellence Leadership Conference, where leaders from our 41 Centers of Excellence — medical centers located around the world with the world's leading Parkinson's specialists — attend and present their cutting-edge research and expert care findings.
While each person with Parkinson’s has individualized symptoms and a different rate of PD progression, NPF hopes that one gift on this list can bring happiness to a person you know with PD, and make life just a little bit easier for him or her.
April is Parkinson's Awareness Month and we want you to advocate for Parkinson's awareness. We have collected 7 inspiring ways you can get involved in the Parkinson's community this month. And don't worry — we have many other ways you can stay involved year-round!
This week the FDA approved the drug Pimavanserin (Nuplazid) for the treatment of Parkinson’s disease psychosis. There has been a critical, unmet need for development of better drugs to address hallucinations and psychosis in the setting of Parkinson's disease. We have learned over many years that typical high potency neuroleptic antipsychotic drugs (e.g.
Beth Coffman lives in Traverse City, Mich., and is 79 years young. She is a wife, mother, grandmother, great grandmother and a member of numerous community groups. Five years ago Beth learned that she has Parkinson’s disease (PD). After retiring from her 40-year teaching career she still strongly believes in the power of information, which is why she calls the National Parkinson Foundation (NPF) Helpline.
Yoga can benefit both persons with PD and their care partners, but often people don’t know how to get started. This is part one; tune in next month for part two!
The last two decades have observed a strong push to initiate dopamine agonist therapy for many Parkinson’s disease patients. However, recently there has been a move away from this approach. The hesitation about agonist therapy has mainly concerned the worrisome impulse control-related side effects, though there are other potential adverse effects reported from agonist use.